Omalizumab relieves seasonal asthma attacks in youth

NIH study finds omalizumab relieves seasonal asthma attacks in youth — Symptoms reduced in children and young people with moderate to severe disease – A drug that targets the antibody immunoglobulin E (IgE), a key player in asthma, nearly eliminated seasonal increases in asthma attacks and decreased asthma symptoms among young people living in inner city environments, a clinical trial sponsored by the National Institutes of Health has found.

Implementing best practices to manage childhood asthma

Childhood asthma foundation invests millions to implement best practices to manage the disease – The Merck Childhood Asthma Network, Inc. (MCAN), announced it is targeting four high risk cities with nearly $4 million for programs that will combine evidence-based science, case management and asthma trigger removal plans to manage a disease that requires more than the right medical care.

Do NOT follow this link or you will be banned from the site!